Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

Prior therapeutic intervention with any of the following:

* Therapeutic anticancer antibodies within 4 weeks (rituximab), except within 6 months for obinutuzumab or a similar investigational type II monoclonal antibody;

* Radio- or toxin-immunoconjugates within 10 weeks;

* Inhibitors of BTK (ibrutinib), PI-3K (idelalisib), BH3-mimetic venetoclax, lenalidomide and other "targeted" therapy (including but not limited to investigational BTK and PI-3K inhibitors, etc.) - within 6 half-lives (i.e., 36 hours for ibrutinib)

* All other chemotherapy, radiation therapy within 3 weeks prior to initiation of therapy

* SYK inhibitors at any time

Inadequate recovery from adverse events related to prior therapy to grade =\< 1 (excluding grade 2 alopecia and neuropathy)

Chronic use of corticosteroids in excess of prednisone 30 mg/day or its equivalent

Stem cell transplant recipients must have no evidence of and not receive treatment for graft-versus-host disease

Concomitant use or use in the prior two weeks of moderate or strong CYP3A and CYP2C9 inducers or strong CYP2C9 inhibitors, including nutraceutical preparations, e.g., grapefruit juice and St John's wort

History prior malignancy except:

* Malignancy treated with curative intent and no known active disease present for \>= 2 years prior to initiation of therapy on current study

* Adequately treated non-melanoma skin cancer or lentigo maligna (melanoma in situ) without evidence of disease

* Adequately treated in situ carcinomas (e.g., cervical, esophageal, etc.) without evidence of disease

* Asymptomatic prostate cancer managed with "watch and wait" strategy

* Myelodysplastic syndrome which is clinically well controlled and no evidence of the cytogenetic abnormalities characteristic of myelodysplasia on the bone marrow at screening

Uncontrolled immune hemolysis or thrombocytopenia (positive direct antiglobulin test in absence of hemolysis or history of immune-mediated cytopenias are not exclusions)

History of human immunodeficiency virus (HIV) infection or active hepatitis B or C

Major surgery (requiring general anesthesia) within 2 weeks prior to initiation of therapy

Inability to swallow and retain an oral medication; patients with clinically significant medical condition of malabsorption, inflammatory bowel disease, chronic conditions which manifest with diarrhea, refractory nausea, vomiting or any other condition that will interfere significantly with drug absorption are excluded; patients must also have adequate venous access

Need for ongoing therapy with proton pump inhibitors; H2 antagonists are allowed

Active uncontrolled infection

Women who are pregnant or lactating

Fertile men or women of childbearing potential unless 1) permanently sterile or 2) using a highly effective measure of contraception such as condoms in males and consistent and correct use of one of the following in females: intrauterine device, tubal sterilization, Essure micro-insert system, vasectomy in the male partner; effective contraception is required for males during treatment with study drug and to continue for 3 months after the last dose of either entospletinib or obinutuzumab, whichever is later; for women, effective contraception is required to continue for 18 months after the last dose of obinutuzumab or for 30 days after the last dose of entospletinib, whichever is later

* Definition of childbearing potential: for this study, a female subject is considered of childbearing potential until becoming post-menopausal unless permanently sterile or with medically documented ovarian failure; women are considered to be in a postmenopausal state when \>= 54 years of age with cessation of previously occurring menses for \>= 12 months without an alternative cause; women of any age with amenorrhea of \>= 12 months may also be considered post-menopausal if their follicle stimulating hormone (FSH) level is in the post-menopausal range and they are not using hormonal contraception or hormonal replacement therapy; permanent sterilization in females includes hysterectomy, bilateral oophorectomy, or bilateral salpingectomy in a female subject of any age; permanent sterilization in males include bilateral orchiectomy or medical documentation of alternative explanation

Any condition for which participation in the study is judged by the Investigator to be detrimental to the patient with inter-current illness or psychiatric/social situations that would jeopardize compliance with study requirements

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

What this study is about

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

What this study is about